Behaviour of Non-Donor Specific Antibodies during Rapid Re-Synthesis of Donor Specific HLA Antibodies after Antibody Incompatible Renal Transplantation
Background HLA directed antibodies play an important role in acute and chronic allograft rejection. During viral infection of a patient with HLA antibodies, the HLA antibody levels may rise even though there is no new immunization with antigen. However it is not known whether the converse occurs, and whether changes on non-donor specific antibodies are associated with any outcomes following HLA antibody incompatible renal transplantation. Methods 55 patients, 31 women and 24 men, who underwent HLAi renal transplant in our center from September 2005 to September 2010 were included in the studies. We analysed the data using two different approaches, based on; i) DSA levels and ii) rejection episode post transplant. HLA antibody levels were measured during the early post transplant period and corresponding CMV, VZV and Anti-HBs IgG antibody levels and blood group IgG, IgM and IgA antibodies were quantified. Results Despite a significant DSA antibody rise no significant non-donor specific HLA antibody, viral or blood group antibody rise was found. In rejection episode analyses, multiple logistic regression modelling showed that change in the DSA was significantly associated with rejection (p = 0.002), even when adjusted for other antibody levels. No other antibody levels were predictive of rejection. Increase in DSA from pre treatment to a post transplant peak of 1000 was equivalent to an increased chance of rejection with an odds ratio of 1.47 (1.08, 2.00). Conclusion In spite of increases or decreases in the DSA levels, there were no changes in the viral or the blood group antibodies in these patients. Thus the DSA rise is specific in contrast to the viral, blood group or third party antibodies post transplantation. Increases in the DSA post transplant in comparison to pre-treatment are strongly associated with occurrence of rejection.
References
[1]
Locke JE, Zachary AA, Warren DS, Segev DL, Houp JA, et al. (2009) Proinflammatory events are associated with significant increases in breadth and strength of HLA-specific antibody. Am J Transplant Sep (9): 2136–9.
[2]
Aiello FB, Calabrese F, Rigotti P, Furian L, Marino S, et al. (2004) Acute rejection and graft survival in renal transplanted patients with viral diseases. Mod Pathol. Feb 17(2): 189–96.
[3]
Forman JP, Tolkoff-Rubin N, Pascual M, Lin J (2004) Hepatitis C, acute humoral rejection, and renal allograft survival. J Am Soc Nephrol. Dec 15(12): 3249–55.
[4]
Morris PJ, Monaco AP (2004) Antibody revisited. Transplantation 78: 179–80.
[5]
Shimmura H, Tanabe K, Ishida H, Tokumoto T, Ishikawa N, et al. (2005) Lack of correlation between results of ABO-incompatible living kidney transplantation and anti-ABO blood type antibody titers under our current immunosuppression. Transplantation. Oct 15 80(7): 985–8.
[6]
Tanabe K, Tokumoto T, Ishida H, Toma H, Nakajima I, et al.. (2003) ABO-incompatible renal transplantation at Tokyo Women’s Medical University. Clinical Transplants, Cecka and Tersaki, 175–181.
[7]
Haas M, Rahman MH, Racusen LC, Kraus ES, Bagnasco SM, et al. (2006) C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: correlation with histologic findings. Am J Transplant 6: 1829–40.
[8]
Tyden G, Kumlien G, Genberg H, Sandberg J, Lundgren T, et al. (2005) ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadosprtion and rituximab. Am J Transplant 5: 145–8.
[9]
Higgins R, Lowe D, Hathaway M, Lam FT, Kashi H, et al. (2009) Rises and falls in donor-specific and third-party HLA antibody levels after antibody incompatible transplantation. Transplantation. Mar 27 87(6): 882–8.
[10]
Briggs D, Zehnder D, Higgins RM (2009) Development of non-donor-specific HLA antibodies after kidney transplantation: frequency and clinical implications. Contrib Nephrol. 162: 107–16.
[11]
Sis B, Mengel M, Haas M, Colvin RB, Halloran PF, et al.. (2010) Banff ’09 Meeting Report: Antibody Mediated Graft Deterioration and Implementation of Banff Working Groups American Journal of Transplantation March Volume 10, Issue 3, pages 464–471.
[12]
Collins AB, Schneeberger EE, Pascual MA, Saidman SL, Williams WW, et al. (1999) Complement activation in acute humoral renal allograft rejection: Diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol 10: 2208–2214.
[13]
Monteiro F, Rodrigues H, Kalil J, Castro MC, Panajotopoulos N, et al. (2012) Pre- and posttransplant monitoring of alloantibodies by complement-dependent cytotoxicity and luminex methodologies in liver transplantation. Transplant Proc. Oct 44(8): 2411–2.
[14]
Krishnan NS, Fleetwood P, Higgins RM, Hathway M, Zehnder D, et al. (2008) Application of flow cytometry to monitor antibody levels in ABO incompatible kidney transplantation. Transplantation. Aug 15 86(3): 474–7.
[15]
Burgess C, Mitchell N, Perry KR (2009) Evaluation report: Evaluation of six Cytomegalovirus. IgG/total antibody kits suitable for use in the UK National Blood Service http://www.hpa.org.uk/webc/HPAwebFile/HP？Aweb_C/1317133422489.
[16]
Tuder RM, Weinberg A, Panajotopoulos N, Kalil J (1994) Cytomegalovirus infection amplifies class I major histocompatibility complex expression on cultured human endothelial cells. J Heart Lung Transplant. Jan-Feb; 13(1 Pt 1): 129–38.
[17]
Di Genova G, Roddick J, McNicholl F, Stevenson FK (2006) Vaccination of human subjects expands both specific and bystander memory T cells but antibody production remains vaccine specific Blood. Apr 1 107(7): 2806–13.
[18]
Candon S, Thervet E, Lebon P, Suberbielle C, Zuber J, et al. (2009) Humoral and cellular immune responses after influenza vaccination in kidney transplant recipients. Am J Transplant. Oct 9(10): 2346–54.
[19]
Avery RK, Michaels M (2008) Update on immunizations in solid organ transplant recipients: what clinicians need to know. Am J Transplant. Jan 8(1): 9–14.
[20]
Vilchez RA, McCurry K, Dauber J, Lacono A, Griffith B, et al. (2002) Influenza virus infection in adult solid organ transplant recipients. Am J Transplant. Mar 2(3): 287–91.
[21]
Adams AB, Pearson TC, Larsen CP (2003) Heterologous immunity: an overlooked barrier to tolerance. Immunol Rev. Dec; 196: 147–60. Review.
[22]
Roddy M, Clemente M, Poggio ED, Bukowski R, Thakkar S, et al. (2005) Heterogeneous alterations in human alloimmunity associated with immunization. Transplantation. Aug 15 80(3): 297–302.
[23]
Bernasconi NL, Traggiai E, Lanzavecchia A (2002) Maintenance of serological memory by polyclonal activation of human memory B cells. Science. Dec 13 298(5601): 2199–202.
[24]
Katerinis I, Hadaya K, Duquesnoy R, Ferrari-Lacraz S, Meier S, et al. (2011) De novo anti-HLA antibody after pandemic H1N1 and seasonal influenza immunization in kidney transplant recipients. Am J Transplant. Aug 11(8): 1727–33.
[25]
Amanna IJ, Carlson NE, Slifka MK (2007) Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 357: 1903–1915.
[26]
Zachary AA, Montgomery RA, Ratner LE, Samaniego-Picota M, Haas M, et al. (2003) Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients. Transplantation. Nov 27 76(10): 1519–25.
[27]
Rentenaar RJ, van Diepen FN, Meijer RT, Surachno S, Wilmink JM, et al. (2002) Immune responsiveness in renal transplant recipients: mycophenolic acid severely depresses humoral immunity in vivo. Kidney Int. Jul 62(1): 319–28.
